(Q48273854)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29318593%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

title

Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29318593%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

0 references

1 reference

chronic lymphocytic leukemia

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29318593%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Carsten Geisler

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29318593%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Paolo Ghia

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29318593%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

8

Stephan Stilgenbauer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29318593%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

author name string

Francesc Bosch

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29318593%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Florence Cymbalista

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29318593%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Peter Hillmen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29318593%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Carol Moreno

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29318593%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

language of work or name

English

0 references

publication date

9 January 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29318593%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Haematology

9 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29318593%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

volume

180

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29318593%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29318593%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

page(s)

666-679

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29318593%20AND%20SRC:MED&resulttype=core&format=json

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

9 April 2020

cites work

1 reference

Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib

21 January 2018

1 reference

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

21 January 2018

1 reference

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

Ibrutinib: a paradigm shift in management of CLL.

21 January 2018

1 reference

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.

21 January 2018

1 reference

Impact of atrial fibrillation on the risk of death: the Framingham Heart Study

21 January 2018

1 reference

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

21 January 2018

1 reference

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

21 January 2018

1 reference

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

21 January 2018

1 reference

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

21 January 2018

1 reference

Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib.

21 January 2018

1 reference

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

21 January 2018

1 reference

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

21 January 2018

1 reference

appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies).

21 January 2018

1 reference

An update for Richter syndrome - new directions and developments

21 January 2018

1 reference

BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia

21 January 2018

1 reference

Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice

21 January 2018

1 reference

Ibrutinib in the real world patient: many lights and some shades.

21 January 2018

1 reference

Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment

21 January 2018

1 reference

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.

21 January 2018

1 reference

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

21 January 2018

1 reference

Ibrutinib-Associated Skin Toxicity: A Case of Maculopapular Rash in a 79-Year Old Caucasian Male Patient with Relapsed Waldenstrom's Macroglobulinemia and Review of the Literature

21 January 2018

1 reference

Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.

21 January 2018

1 reference

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.

21 January 2018

1 reference

Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.

21 January 2018

1 reference

Racial differences in three major NHL subtypes: descriptive epidemiology.

21 January 2018

1 reference

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

21 January 2018

1 reference

2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension

21 January 2018

1 reference

Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia

21 January 2018

1 reference

Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis

21 January 2018

1 reference

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

21 January 2018

1 reference

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

21 January 2018

1 reference

Survival for patients with chronic leukemias in the US and Britain: Age-related disparities and changes in the early 21st century

21 January 2018

1 reference

Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia

21 January 2018

1 reference

Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).

21 January 2018

1 reference

Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies

21 January 2018

1 reference

Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib

21 January 2018

1 reference

Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients

21 January 2018

1 reference

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib

21 January 2018

1 reference

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial

21 January 2018

1 reference

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017.

21 January 2018

1 reference

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group

21 January 2018

1 reference

How I manage ibrutinib-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

21 January 2018

1 reference

Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling

21 January 2018

1 reference

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.15080

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29318593%20AND%20SRC:MED&resulttype=core&format=json

release_opndewbjkzgbjejub43v4xanwa

9 April 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/opndewbjkzgbjejub43v4xanwa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference